Multifunctional CRISPR/Cas9 with engineered immunosilenced human T cell epitopes
S. R. Ferdosi, R. Ewaisha, F. Moghadam, S. Krishna, J. G. Park, M. R. Ebrahimkhani, S. Kiani, K. S. Anderson
This study shows that Cas9 can be modified to reduce immunogenicity while maintaining its function.
bioRxiv · Jul 2, 2018Immunology